China Pharma Holdings, Inc. CPHI
0.75
0.01
1.35%
as of 25 Sep
- Market cap
- $31.8M
- P/E
- 0.0×
Follow CPHI
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (20.99%) | (16.12%) | (20.91%) | (42.98%) |
+8 more TTM periods Free account |
|
| (15.30%) | (11.94%) | (13.89%) | (21.80%) | ||
ROIC |
(7.23%) | (5.80%) | (8.31%) | (20.27%) | |
Return on Tangible Assets |
307.50% | 369.24% | 481.51% | (1,525.54%) | |
Average Days of Receivables |
23.15 | 23.58 | 25.60 | 25.75 | |
Free Cash Flow per Share |
0.00 | 0.01 | (0.01) | (0.04) | |
Free Cash Flow |
(0.14) | 0.17 | (0.04) | (0.16) | |
Capital Expenditures |
— | — | (0.19) | (0.46) | |
Piotroski F-Score |
4.00 | 5.00 | 5.00 | 5.00 | |
| Other line items | |||||
Cash ROIC |
(0.37%) | 0.43% | 0.59% | 2.79% | |
Accounts Receivable Turnover |
13.85 | 12.76 | 14.99 | 12.17 | |
Accounts Payable Turnover |
5.46 | 5.34 | 7.66 | 9.19 | |
Inventory Turnover |
2.27 | 2.13 | 2.20 | 2.17 | |
Average Days of Payables |
77.57 | 82.54 | 76.06 | 47.80 | |
Days of Inventory on Hand |
143.98 | 147.75 | 138.40 | 133.94 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
8.51% | 8.40% | 6.78% | 2.26% | |
Selling, General and Administrative Expense of Revenue |
115.06% | 89.06% | 68.22% | 65.97% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.03 | (0.05) | (0.05) | (0.09) | |
Depreciation/Fixed assets |
0.72 | 0.52 | 0.36 | 0.34 | |
Capex/Depreciation |
0.00 | 0.00 | (0.12) | (0.30) | |
Revenue per Share |
0.10 | 0.16 | 0.97 | 1.05 | |
Operating CF per Share |
0.00 | 0.01 | 0.03 | 0.08 | |
Capex per Share |
0.00 | 0.00 | (0.04) | (0.12) | |
Capex to Sales |
0.00 | 0.00 | 0.05 | 0.11 | |
Net Profit Margin |
(114.33%) | (88.82%) | (76.92%) | (78.72%) |
Columns are period end dates